Anges Inc. has entered into a sponsored research agreement with Stanford University School of Medicine for the development of novel cancer therapies using genome editing technology. The parties aim to ...

MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025NHP Proof-of-Concept Anticipated for Secreted Protein ...

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...

We are excited to welcome Eric to our Board of Directors,” said Brian C. Thomas, PhD, CEO and founder of Metagenomi. “His tremendous track record in the pharmaceutical industry as well as his ...

The de-extinction company led by CEO Ben Lamm has raked in $435 million in funding since its launch. He believes it has ...

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious ...

Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...

Genetic changes are a significant cause of infertility, impacting over 15% of the global population. TLE6, a major protein ...

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

HC Wainwright reiterated their buy rating on shares of Precision BioSciences (NASDAQ:DTIL – Free Report) in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has ...

Panelists from China, India, and Vietnam speak about the threat the fungal disease poses on each country and the best ...

CRISPR-Cas systems have been exploited for targeted genome editing. Although compact Un1Cas12f1 has improved, low gene editing activity was observed in some target genes. Here, authors developed ...